ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2010
5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.Headache · 2020Trial
- Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.The journal of headache and pain · 2019Trial
- Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN.Cephalalgia : an international journal of headache · 2019Trial
- The prodrome of migraine: mechanistic insights and emerging therapeutic strategies.Frontiers in neurology · 2024Review
- The role of hippocampal 5-HTNaunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Article
- CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine.Journal of clinical medicine · 2021Review
- The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.The journal of headache and pain · 2019Review
- The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine.Therapeutic advances in neurological disorders · 2015Review
- New treatments for headache.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2014Review
- Sumatriptan iontophoretic transdermal system: a review of its use in patients with acute migraine.Drugs · 2013Review
- The pipeline in headache therapy.CNS drugs · 2013Review
- Update on future headache treatments.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2013Review
- Advances in drug development for acute migraine.Drugs · 2012Article
- Where does a migraine attack originate? In the brainstem.Journal of neural transmission (Vienna, Austria : 1996) · 2012Review
- Identification of molecular genetic factors that influence migraine.Molecular genetics and genomics : MGG · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a debilitating disorder of the CNS. Although therapeutic options for migraine attacks have tremendously advanced with the development of triptans more than a decade ago, several conditions (such as vascular disease) restrict their use. Moreover, some patients do not respond to triptans and other currently available medications. Therefore, treatment alternatives are needed. Study data show that 5-HT(1F) receptor agonists successfully abort migraine attacks. These data also suggest a favorable vascular side-effect profile of these substances, which could be beneficial for migraine treatment in subjects with cardiac or vascular disease. We discuss the current knowledge of 5-HT(1F) receptor-mediated effects, in part by comparing them to triptans, and we also summarize data from basic research and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.